, Volume 14, Issue 2, pp 143–148 | Cite as

Cost-of-Illness Studies

Useful for Health Policy?
Current Opinion Cost-of-Illness Studies and Health Policy


A sample of cost-of-illness (COI) studies was reviewed, which included studies for specific diseases (‘specific’ studies) as well as those for the entire range of diseases (‘general’ studies).

Theoretically, COI studies may deliver suitable information for health policy and rational healthcare spending. In practice, however, the informative value of ‘specific’ prevalence-based COI studies is very limited. A static picture of costs is presented in these studies, as trends in costs are not being described or explained by factors such as demography, epidemiology and technology. No practical link is offered between COI estimates and economic evaluation. Incidence-based COI studies can provide more relevant information for economic evaluation studies.

It appears more useful to perform general COI studies, as these provide comparable estimates of disease costs and put cost estimates in a total healthcare perspective. Compared with specific COI studies, general COI studies better facilitate the analysis and projection of trends in costs, for example due to aging.


  1. 1.
    Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy 1987; 8: 317–23CrossRefGoogle Scholar
  2. 2.
    Hodgson TA. Cost of illness studies: no aid to decision-making? Comments on the second opinion by Shiell et al. Health Policy 1989; 11: 57–60PubMedCrossRefGoogle Scholar
  3. 3.
    Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536–52PubMedCrossRefGoogle Scholar
  4. 4.
    van Roijen L, Rutten FFH. Cost of illness studies, policy relevance and methods [in Dutch]. T Soc Gezondheidsz 1997; 75: 184–8Google Scholar
  5. 5.
    Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513–22PubMedCrossRefGoogle Scholar
  6. 6.
    Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636–42PubMedCrossRefGoogle Scholar
  7. 7.
    Beeck EF, Roijen Van L, Mackenbach JP. Medical costs and economic production losses due to injuries in the Netherlands. J Trauma Inj Infect Crit Care 1997; 42 (6): 1116–22CrossRefGoogle Scholar
  8. 8.
    Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595–600PubMedCrossRefGoogle Scholar
  9. 9.
    Evers SMAA, Engel GL, Ament AJHA. Cost of stroke in the Netherlands from a societal perspective. Stroke 1997; 28: 1375–81PubMedCrossRefGoogle Scholar
  10. 10.
    Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care, Pharmacoeconomics 1995; 7 (4): 284–91PubMedCrossRefGoogle Scholar
  11. 11.
    Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405–18PubMedGoogle Scholar
  12. 12.
    Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 16: 665–73CrossRefGoogle Scholar
  13. 13.
    Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997; 19: 128–38PubMedCrossRefGoogle Scholar
  14. 14.
    Krahn MD, Berka C, Langlois P, et al. Direct and indirect costs of asthma in Canada 1990. Can Med Assosc J 1996; 154 (6): 821–31Google Scholar
  15. 15.
    Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994; 9: 229–43PubMedCrossRefGoogle Scholar
  16. 16.
    Lissovoy de G, Lazarus SS. The economic cost of migraine. Neurology 1994; 44 Suppl. 4: s56–62Google Scholar
  17. 17.
    Magnusson S. Treatment of rheumatoid arthritis: does it affect society’s cost for the disease? Br J Rheumatol 1996; 35: 791–5PubMedCrossRefGoogle Scholar
  18. 18.
    Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1): 22–7PubMedGoogle Scholar
  19. 19.
    Max W. The cost of alzheimer’s disease. Pharmacoeconomics 1996; 9 (1): 5–10PubMedCrossRefGoogle Scholar
  20. 20.
    McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781–90PubMedCrossRefGoogle Scholar
  21. 21.
    Mellis CM, Peat JK, Woolcock AJ. The cost of asthma. Pharmacoeconomics 1993; 3 (3): 205–19PubMedCrossRefGoogle Scholar
  22. 22.
    Midgard R, Riise T, Nyland H. Impairment, disability and handicap in multiple sclerosis. J Neurol 1996; 243: 337–44PubMedCrossRefGoogle Scholar
  23. 23.
    Rupp A. The economic consequences of not treating depression. Br J Psychiatry 1995; 166: 29–33CrossRefGoogle Scholar
  24. 24.
    Simell TT, Sintonen H, Hahl J, et al. Costs of insulin-dependent diabetes mellitus. Pharmacoeconomics 1996; 9 (1): 24–38PubMedCrossRefGoogle Scholar
  25. 25.
    Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16: 873–97PubMedGoogle Scholar
  26. 26.
    Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Pharmacoeconomics 1995; 8 (3): 199–222PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss KB, Sullivan SD. Socio-economic burden of asthma, allergy, and other atopic illnesses. Pediatr Allergy Immunol 1994; 5 Suppl. 1: 7–12CrossRefGoogle Scholar
  28. 28.
    Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995; 40: s60–7PubMedGoogle Scholar
  29. 29.
    Warner DC, McCandless RR, De Nino LA, et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996; 19: 1416–9PubMedCrossRefGoogle Scholar
  30. 30.
    Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 1351–62PubMedCrossRefGoogle Scholar
  31. 31.
    Koopmanschap MA, Rutten FFH, Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89PubMedCrossRefGoogle Scholar
  32. 32.
    Koopmanschap MA, Rutten FFH. Indirect costs: the consequences of production loss or increased costs of production. Med Care 1996; 34 (12): DS59–68PubMedGoogle Scholar
  33. 33.
    Drummond MF, O’Brien BJ, Stoddard GL, et al. Methods for economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997Google Scholar
  34. 34.
    Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996Google Scholar
  35. 35.
    Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for economic evaluations of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994Google Scholar
  36. 36.
    Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Woden: Australian Department of Health, Housing and Community Services, 1990Google Scholar
  37. 37.
    Health Care Economics Consensus Group. German recommendations on health care cost analysis: Hannover Consensus. PharmacoEcon Outcomes News 1996; 56: 4–6Google Scholar
  38. 38.
    Mathers C, Penm R, Carter R, et al. Health system costs of diseases and injury in Australia 1993-94: an analysis of costs, services use and mortality for major disease and injury groups. Canberra: Australian Institute of Health and Welfare, 1998Google Scholar
  39. 39.
    Moore R, Mao Y, Zhang J, et al. Economic burden of illness in Canada, 1993. Ottawa: Ministry of Public Works and Government Services, 1997Google Scholar
  40. 40.
    National Health Service (NHS) Executive. Burdens of disease: a discussion document. Wetherby: Office for National Statistics, 1996Google Scholar
  41. 41.
    Polder JJ, Meerding WJ, Koopmanschap MA, et al. Costs of diseases in the Netherlands 1994 [in Dutch]. Rotterdam: Erasmus University, 1997.Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Institute for Medical Technology Assessment (IMTA)Erasmus University RotterdamRotterdamThe Netherlands

Personalised recommendations